The decision comes right on the heels of the FDA's rejection of Merck & Co's rival oral P2X3 antagonist gefapixant, which was also attributed to concerns about the safety of the drug. In a ...

Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

Gefapixant, a novel oral medication, has shown promise in clinical trials for patients with refractory chronic cough and unexplained chronic cough. In two large phase 3 trials, COUGH-1 and COUGH-2 ...